Lilly to pay $1.4B for alleged off-label promotion
Pharma Compliance Alert, January 21, 2009
Eli Lilly’s tab for allegedly promoting its antipsychotic Zyprexa for off-label uses topped $2.6 billion after it agreed to pay $1.42 billion to resolve civil and criminal allegations with the federal government.
The settlement includes a $515 million criminal fine, the largest ever in a healthcare case, and the largest criminal fine for an individual corporation ever imposed in a United States criminal prosecution of any kind, according to a Department of Justice (DOJ) press release.
Click here to read more.
Comments
0 comments on “Lilly to pay $1.4B for alleged off-label promotion ”
Related Products
Most Popular
- Articles
-
- HIPAA Q&A: Flu shot requirement for hospital employees
- Running an effective peer review committee meeting
- HealthDataInsights posts new issues for medical necessity claims
- Sneak Peek: Effort underway to establish caseload benchmarks
- Q/A: Coding for telescopic intraocular lens
- New FAQ posted on storing laryngoscope blades
- Tip: Perform your own internal investigation prior to government audit
- HIPAA 5010 deadline extended, but threat remains, says AMA
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- E-mailed
-
- Running an effective peer review committee meeting
- HIPAA Q&A: Flu shot requirement for hospital employees
- HHS task force: Consider privacy, security with text messages
- What does case-mix index mean to you?
- Q/A: Coding for telescopic intraocular lens
- Q/A: Correct use of modifier -PT
- Tip: Correctly code bilateral pain management procedures
- "Wall fountains" may be spreading Legionnaires to patients, visitors
- 2012 CPT code changes for ASCs: Shoulder and knee scopes and pain management
- COT basics to best
- Searched
